HK Stock Market Move | SBP GROUP (01177) rises nearly 3%; latest research results for TQ-A3334 and Bepirovirsen to be announced at 2026 AASLD
SBP GROUP (01177) rose nearly 3%, up 2.32% as of press time, at HK$5.29, with a turnover of HK$47.9849 million.
SBP GROUP (01177) rose nearly 3%, up 2.32% as of press time, at HK$5.29, with a turnover of HK$47.9849 million.
On the news front, on October 14, SBP GROUP issued an announcement that a clinical study result of TQ-A3334 (TLR7 agonist), a National Class 1 innovative drug independently developed by the company's subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Chia Tai Tianqing), has been selected as a late-breaking abstract (LBA) for the 2026 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and will be presented as an oral presentation; Bepirovirsen (ASO), a strategic collaboration product between Chia Tai Tianqing and GlaxoSmithKline (GSK), has been selected for 2 oral presentations and 8 poster presentations (including 1 distinguished poster).
Related Articles
HK Stock Market Move | Dajin Heavy Industry (01081) fell over 6% again, hitting a new post-listing low; the stock has pulled back more than 30% over the past five trading days.
Cleveland-Cliffs (CLF.US) earnings are coming again! Options traders are positioning early to guard against sharp stock price swings.
Citi: Expects BILIBILI-W (09626) Q3 results to be in line with expectations; advertising revenue dragged by macro conditions.
HK Stock Market Move | Dajin Heavy Industry (01081) fell over 6% again, hitting a new post-listing low; the stock has pulled back more than 30% over the past five trading days.
Cleveland-Cliffs (CLF.US) earnings are coming again! Options traders are positioning early to guard against sharp stock price swings.
Citi: Expects BILIBILI-W (09626) Q3 results to be in line with expectations; advertising revenue dragged by macro conditions.
